Free Trial

Safety Shot (NASDAQ:SHOT) Rating Increased to Hold at Wall Street Zen

Safety Shot logo with Medical background

Key Points

  • Safety Shot has been upgraded from a "sell" rating to a "hold" rating by Wall Street Zen, indicating a potential shift in investor sentiment.
  • Shares of Safety Shot (NASDAQ:SHOT) increased by 5.9% on the news, with the stock currently priced at $0.65.
  • Institutional investors have shown increased interest, with notable position raises by firms such as Tyche Wealth Partners LLC and Jane Street Group LLC, indicating growing confidence in the company's prospects.
  • Interested in Safety Shot? Here are five stocks we like better.

Wall Street Zen upgraded shares of Safety Shot (NASDAQ:SHOT - Free Report) from a sell rating to a hold rating in a report issued on Saturday morning.

Safety Shot Trading Down 1.4%

SHOT stock traded down $0.0071 during midday trading on Friday, reaching $0.4864. 2,652,323 shares of the company's stock traded hands, compared to its average volume of 11,190,213. The company has a 50-day simple moving average of $0.55 and a two-hundred day simple moving average of $0.48. Safety Shot has a 1-year low of $0.23 and a 1-year high of $1.77.

Safety Shot (NASDAQ:SHOT - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.03) earnings per share for the quarter. The company had revenue of $0.45 million during the quarter.

Institutional Investors Weigh In On Safety Shot

Several hedge funds and other institutional investors have recently made changes to their positions in SHOT. XTX Topco Ltd acquired a new stake in shares of Safety Shot in the 1st quarter valued at $59,000. Jane Street Group LLC increased its stake in shares of Safety Shot by 397.7% in the 4th quarter. Jane Street Group LLC now owns 102,267 shares of the company's stock valued at $74,000 after buying an additional 81,720 shares during the period. Geode Capital Management LLC increased its stake in shares of Safety Shot by 13.3% in the 4th quarter. Geode Capital Management LLC now owns 491,743 shares of the company's stock valued at $354,000 after buying an additional 57,876 shares during the period. Finally, Tyche Wealth Partners LLC increased its stake in shares of Safety Shot by 142.9% in the 2nd quarter. Tyche Wealth Partners LLC now owns 85,000 shares of the company's stock valued at $28,000 after buying an additional 50,000 shares during the period. 12.55% of the stock is owned by institutional investors and hedge funds.

About Safety Shot

(Get Free Report)

Safety Shot, Inc, a wellness and functional beverage company, researches and develops over-the-counter products and intellectual property. The company offers Safety Shot Beverage, an over-the-counter drink that lowers blood alcohol content. It also develops Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women's sexual wellness; and NoStingz, a jellyfish sting prevention sunscreen.

Featured Stories

Should You Invest $1,000 in Safety Shot Right Now?

Before you consider Safety Shot, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Safety Shot wasn't on the list.

While Safety Shot currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.